Lyell aims to follow Juno, Sana as Wall Street cools to biotech IPOs
Bio Pharma Dive
MAY 26, 2021
The ambitious cell therapy developer, which has already raised nearly $1 billion from investors, will test the IPO market just as the pace and performance of recent biotech offerings have slowed considerably.
Let's personalize your content